{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-046852","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.719476+00:00","generated_at":"2026-05-30T01:50:59.873377+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avalo receives $69.4M from full warrant exercise; cash runway into at least 2027","bullets":["Gross proceeds of $69.4M from exercise of 11,967,526 warrants at $5.796933/share; total private placement proceeds now $185M.","Cash runway expected into at least 2027, funding Phase 2 LOTUS trial and expansion of AVTX-009 program.","As of Nov 8, 2024: 10,463,633 common shares outstanding; 24,895.92 Series C Preferred shares convertible into 24.9M common shares subject to ownership limits.","CEO states focus on hidradenitis suppurativa trial and identifying next inflammatory indication for AVTX-009."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-046852","json":"https://secwatch.observer/filing/0001628280-24-046852.json","markdown":"https://secwatch.observer/filing/0001628280-24-046852.md","text":"https://secwatch.observer/filing/0001628280-24-046852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024046852/0001628280-24-046852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024046852/avtx-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:50:59.873377+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}